Stay updated with breaking news from Johnson Innovative. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with...
SAN DIEGO--(BUSINESS WIRE)--Jun 3, 2024--
The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody...
By Denny Jacob Johnson & Johnson entered into an agreement with Numab Therapeutics to acquire the global rights for bispecific antibody NM26 in an all-cash deal valued at $1.25 billion. ...
Media contacts: Investor contact: ...